home / stock / mnpr / mnpr news

MNPR News and Press, Monopar Therapeutics Inc. From 01/18/23

Stock Information
Company Name: Monopar Therapeutics Inc.
Stock Symbol: MNPR
Market: NASDAQ
Website: monopartx.com
Menu
MNPR MNPR Quote MNPR Short MNPR News MNPR Articles MNPR Message Board
Get MNPR Alerts

News, Short Squeeze, Breakout and More Instantly...
MNPR - Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

WILMETTE, Ill., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the positive recommenda...
MNPR - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Pharmaceutical and healthcare stocks dominate our lists this morning with ...

MNPR - Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

WILMETTE, Ill, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released promising data with ...

MNPR - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a look at the biggest pre-market stock movers for Thursday! Moinvg stocks is a reverse stock split, earnings reports, clinical trial data and...
MNPR - Monopar stock falls 20% amid preliminary phase 1 data for cancer drug camsirubicin

Monopar Therapeutics ( NASDAQ: MNPR ) reported data from an ongoing phase 1b trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Camsirubicin is a novel proprietary analog of cancer drug doxorubicin. The phase 1b trial enrolled 11 patie...

MNPR - Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

WILMETTE, Ill., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today released encouraging d...

MNPR - Monopar Therapeutics GAAP EPS of -$0.19 beats by $0.02

Monopar Therapeutics press release ( NASDAQ: MNPR ): Q3 GAAP EPS of -$0.19 beats by $0.02 . Cash and cash equivalents as of September 30, 2022, were $14.3 million. For further details see: Monopar Therapeutics GAAP EPS of -$0.19 beats by $0.02

MNPR - Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

Validive ® Phase 2b/3 Interim Analysis on Track for Q1 2023 Camsirubicin Clinical Data at CTOS 2022 Next Week MNPR-202 Preclinical Data at ASH 2022 in December WILMETTE, Ill., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc...

MNPR - Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical ...

MNPR - Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting

WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced th...
Previous 10 Next 10